HealthDay 
(2/15, Preidt) reports, "Vitamin D therapy does not improve heart
health in people with chronic kidney disease [CKD]," according to a study published in the Journal of the American Medical Association.
(2/15, Preidt) reports, "Vitamin D therapy does not improve heart
health in people with chronic kidney disease [CKD]," according to a study published in the Journal of the American Medical Association.
MedPage Today
(2/15, Walsh) reports, "After 48 weeks of treatment, the change in left
ventricular mass was similar among patients receiving the active
vitamin D compound paricalcitol (Zemplar) and patients receiving placebo
(0.34 g/m2.7 compared with -0.07 g/m2.7, P=0.06)." Researchers also
found that "there was no difference in peak early diastolic lateral
mitral annular tissue velocity, which was −0.01 cm/second in the vitamin
D group and −0.30 cm/second in the placebo group (P=0.93)."
(2/15, Walsh) reports, "After 48 weeks of treatment, the change in left
ventricular mass was similar among patients receiving the active
vitamin D compound paricalcitol (Zemplar) and patients receiving placebo
(0.34 g/m2.7 compared with -0.07 g/m2.7, P=0.06)." Researchers also
found that "there was no difference in peak early diastolic lateral
mitral annular tissue velocity, which was −0.01 cm/second in the vitamin
D group and −0.30 cm/second in the placebo group (P=0.93)."
HeartWire
(2/15, Wood) reports that "cardiac hospitalizations were slightly lower
in the vitamin-D group as compared with the placebo group, while
increases in plasma B-type natriuretic-peptide (BNP) were less marked in
the paricalcitol group; paricalcitol also increased serum creatinine
and decreased creatinine-based measures of estimated glomerular
filtration rate (eGFR)." The investigators also found that "patients
taking paricalcitol also had a slightly higher number of adverse events,
mostly due to hypercalcemia."
(2/15, Wood) reports that "cardiac hospitalizations were slightly lower
in the vitamin-D group as compared with the placebo group, while
increases in plasma B-type natriuretic-peptide (BNP) were less marked in
the paricalcitol group; paricalcitol also increased serum creatinine
and decreased creatinine-based measures of estimated glomerular
filtration rate (eGFR)." The investigators also found that "patients
taking paricalcitol also had a slightly higher number of adverse events,
mostly due to hypercalcemia."
No comments:
Post a Comment